-
Lilly latone reduces cardiovascular events in people with type 2 diabetes
Time of Update: 2020-06-11
recently, Lilly announced that its weekly administration of polyglycin in the REWIND study showed that diglyglyceridesin significantly reduced major cardiovascular adverse events (MACE), that includ
-
ADG-106, a leading product of Tianxing Pharmaceuticals, has been approved for clinical trials issued by China's State Drug Administration
Time of Update: 2020-06-11
today (November 1), Tianxing Pharmaceuticals announced that Company's (the of independently developed leading product s (the National Medicines (The National Medicines Administration of China
-
Johnson and Johnson and AbbVie's Imbruvica receive FDA approval for treatment of rare blood tumorly lymphocyte lymphoma
Time of Update: 2020-06-11
recently, Johnson and Johnson (and AbbVie's Imbruvica) were awarded the U.S Food Medicines (Supervisory Authority) for treatment of rare blood tumorly lymphocytic lymphoma imbruvica Imbruvica
-
Agios Pharmaceuticals cancer drug TIBSOVO (ivosidenib) gets FDA approval
Time of Update: 2020-06-11
recently, cancer bio Pharmaceutical ( Pharmaceuticals) announced that its anticancer drug (ivosidenib) was approved by the U.S FDA (for use in an adult with a testing (Abbott RealTimeIDH1 a
-
"first-in-class" anti-cancer candidate drug enters clinical Phase 1 trial for the treatment of patients with recurrent brain tumors
Time of Update: 2020-06-11
Today, Moleculin Biotech (announced the company's "first-in-class" anticancer candidate drug (entering the clinical phase 1 trial for the treatment of patients with recurrent brain tumors) ()
-
Sandoz's infliximab biosimilar zeslym approved by the European Commission
Time of Update: 2020-06-11
recently, Sandoz announced that its company, , which produces the infliximab biosimilar drug Zessly, has been granted access to the European market through european commission approval about Infli
-
Sesen Bio's new bladder cancer drug, Vicinium, gets fast-track status from FDA
Time of Update: 2020-06-11
recently, Sesen Bio (announced that its leading product (the U.S FDA (granted fast-track eligibility) for the treatment of patients with highly graded non-muscular leachate bladder cancer (hig
-
FDA approves AstraZeneca's Lumoxiti intravenous agent for treatment of adult patients with recurrent or refractory hair cell leukemia
Time of Update: 2020-06-11
recently, the United States The FDA (announced the approval of AstraZeneca 's Lumoxoxiti (moxetumomab pasudotox-tdfk) intravenous agent for the treatment of recurrent or refractory hair cell leu
-
FDA approves AstraZeneca Lumoxiti intravenous agent for treatment of adult patients with recurrent or refractory hair cell leukemia
Time of Update: 2020-06-11
HCL is a rare, slow-growing blood cancer caused by the bone marrow producing too many B lymphocytes As leukaemia cells increase, the number of healthy (white blood cells, red blood cells, and plate
-
FDA accepts sacituzumab govitecan application for listing of biological products for triple-negative breast cancer treatment
Time of Update: 2020-06-11
recently, bio Pharmaceuticals (The Company that the U.S FDA (govitecan, which has accepted its drug ( and has been treated at least twice in the past for metastatic triple-negative breast canc
-
Phase 2b study of diluted polyvicanone iodine in Veloce's new DMSO solvent system yielded positive results
Time of Update: 2020-06-11
yesterday (October 8), Veloce BioPharma, LLC ("Veloce")," announced positive results from its Phase 2 b study on dilution of polyvione iodine in the new DMSO solvent system, which is used for local
-
FDA approves Novartis' new oral targeted cancer drug Kisqali for treatment of patients with advanced or metastatic breast cancer
Time of Update: 2020-06-11
recently, Swiss Pharmaceutical scoundrel Novartis announced that the U.S Food and Drug ( FDA () has approved the new oral targeting anti-cancer drug Kisqali (ribociclib) for the treatment of pat
-
European Commission approves Sanofi nanoantibody drug Cablivi for treatment of adult patients with aTTP
Time of Update: 2020-06-11
aTTP is a life-threatening, autoimmune-based clotting disorder characterized by the formation of large numbers of blood clots in small blood vessels throughout the body, leading to severe thrombocyto
-
EC approves Keytruda joint Alimta first-line treatment of metastatic non-squamous non-small cell lung cancer adult patients
Time of Update: 2020-06-11
recently, the cancer immunotherapy giant Merck and Co announced that the European Commission (EC) has approved the PD-1 tumor immunotherapy Keytruda (pembrolizumab, Pablo bead monoantigen) combined
-
Cinda Biorecoa Whole Human Source Anti-CD47 monoclonal antibody body approved by FDA for drug clinical trial
Time of Update: 2020-06-11
recently, Cinda Bio announced that the Company (developed recombinant whole-human source anti-CD47 monoclonal antibody (research code: IBI-188), has been the United States Food Drug (the Drug
-
FDA approves CT-P10 for treatment of B-cell non-Hodgkin lymphoma
Time of Update: 2020-06-11
recently, Celltrion (and its partner, Teva Pharmaceutical Industries) announced that the U.S the FDA (The Oncology Drug (Consulting (the Committee recommended the FDA's approval of CT-P10 for
-
FDA accepts Coagadex's application for license to supplementary biologics
Time of Update: 2020-06-11
recently, Bio Products Laboratory (BPL) (announcing that the U.S FDA ( has accepted the company's application for a supplementary biologic license (sBLA) for Coagadex and granted it priority revi
-
BMS Announces Phase II ELOQUENT-3 Study Reaches Major End
Time of Update: 2020-06-11
recently, BMS announced at the EHA 2018 annual meeting that the second phase of the ELOQUENT-3 study reached its main endpoint, with empliciti (elotuzumab) combining pomaduamine and low-dose dexamet
-
New drug for the treatment of Alzheimer's disease, "Glucosaccharide Diacid (GV-971)" successfully completed clinical Phase 3 trial
Time of Update: 2020-06-11
Recently, the Shanghai Green Valley Pharmaceutical (Limited Company (announced by The University of China, the Chinese Academy of Sciences, Shanghai Pharmaceutical (Research Institute and Shan
-
Lilalutide and Lilalutide injections in Tonghua Dongbao have been approved by the State Drug Administration
Time of Update: 2020-06-11
October 11, Tonghua Dongbao Pharmaceuticals Limited Company ("Tonghua Dongbao") announcement shows that the company declared liraglutide (receiving number CXSL1700142), liraglutide injection (rece
